These findings suggest that 5-DR, a novel NLRP3 inflammasome inhibitor, can mitigate inflammation in LPS-induced ALI and holds promise as a potential therapeutic agent for reducing ALI in clinical practice. This evidence concerns the gene NLRP3 and acute respiratory distress syndrome.